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RELATIONSHIP BETWEEN RESPIRATORY, ENDOCRINE,
AND COGNITIVE-EMOTIONAL FACTORS IN RESPONSE
TO A PHARMACOLOGICAL PANICOGEN
Mark Lyubkin, M.D., Nicholas D. Giardino, Ph.D., and James L. Abelson, M.D. Ph.D.
Background: The cholecystokinin agonist pentagastrin has been used to study
panic attacks in the laboratory and to investigate hypothalamic–pituitary–
adrenal axis activity. Its mechanism of panicogenesis remains unclear. Data
from other models suggest that respiratory stimulation itself may induce panic,
but pentagastrin’s effects on respiration are not well established. Data from
another model also suggest links between respiratory and HPA axis reactivity
and cognitive modulation of both. To further explore these phenomena, we added
respiratory measures to a study of cognitive modulation of HPA and anxiety
responses to pentagastrin. Methods: Healthy subjects received pentagastrin and
placebo injections, with measurement of cortisol and subjective responses, on two
different laboratory visits. They were randomly assigned to receive standard
instructions or one of two versions of previously studied cognitive interventions
(to either facilitate coping or increase sense of control), given before each visit.
Capnograph measures of heart rate (HR), respiratory rate (RR), and end-tidal
pCO2 were obtained on 24 subjects. Results: Relative to placebo, pentagastrin
induced a significant decline in pCO2 with no change in RR. Cortisol and HR
increased, as expected. Cognitive intervention reduced the hyperventilatory
response to pentagastrin. Conclusions: Pentagastrin stimulates respiration,
likely via increases in tidal volume. Respiratory stimulation could play a role in
its panicogenic potency, though perhaps indirectly. As with HPA axis responses,
higher-level brain processes may be capable of modulating pentagastrin-induced
hyperventilation. This model may be useful for further study of cortical/
cognitive control of interacting emotional, respiratory, and neuroendocrine
sensitivities, with potential relevance to panic pathophysiology. Depression and
Anxiety 27:1011–1016, 2010. r 2010 Wiley-Liss, Inc.
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INTRODUCTION
Cholecystokinin (CCK) is a widely distributed CNS
peptide thought to play a mediating role in anxiety.[1]
Human studies have shown that the CCK-B agonists,
CCK-4 and pentagastrin, can produce panic attacks in
laboratory models,[2–4] but mechanisms of panicogen-
esis remain unclear. CCK-B agonists may have direct
effects on neural regions mediating components of
anxiety or panic responses, or simply produce side
effects that are interpreted as threatening. Effects on
respiration may also play a role. Direct respiratory
stimulation can itself induce panic,[5,6] but pentagastrin’s
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impact on respiration is not well studied. CCK-B
agonists may increase respiration by increasing tidal
volume (Vt) and not respiratory rate (RR),[7] though
there is some evidence they can increase both Vt and
RR. To our knowledge, there has only been one study
that examined the effect of CCK-B on end-tidal, partial
pressure of carbon dioxide (PETCO2) and its associa-
tion with panic-like symptoms in healthy humans. The
study found that CCK-B did not affect respiratory
parameters,[8] but it used a relatively low dose of the
CCK-B agonist in order to demonstrate that increase
in general arousal does not drive respiratory para-
meters, and hypothesized a link between CCK-B panic
and respiratory parameters that would likely be seen
with higher doses of CCK panicogens. Further under-
standing the normal respiratory effects of laboratory
panicogens is important, because sensitivity to PETCO2
in brainstem suffocation alarm centers has been
proposed as a putative mechanism underlying panic
disorder.[9,10]
There is evidence that psychological or cognitive
interventions can reduce panic symptom intensity in
laboratory models, in part by affecting respiratory
measures. Research using the respiratory stimulant
doxapram has shown that a cognitive intervention (CI)
designed to reduce ‘‘catastrophic cognitions’’ and
increase sense of control can significantly attenuate
hyperventilatory and panic responses in panic patients.[6]
This suggests that respiratory effects of CCK-B agonists
may also be modulated by higher cortical processes.
The relative contribution of brainstem-level super-
sensitivities and top-down modulatory dysfunction
to respiratory abnormalities in panic has not been
extensively examined.
In addition to anxiogenesis, CCK-B agonism also
activates the hypothalamic-pituitary-adrenal (HPA)
axis, a principal neuroendocrine stress response sys-
tem,[11–13] but there seems to be little relationship
between anxiety and stress system responses.[3,14,15]
These data suggest dissociation between autonomic,
anxiety, and HPA response to pentagastrin. However,
there is evidence that HPA activation and respiratory
irregularity are closely linked to each other in panic
patients in the doxapram model,[16] suggesting poten-
tial value in further examination of cross-system
linkages in laboratory models of panic.
To further explore the impact of CCK-B agonism on
respiration, we added respiratory monitoring to a larger
neuroendocrine study investigating the effects of cogni-
tive/emotional factors as modulators of pentagastrin-
induced HPA axis activity in healthy subjects. We
examined effects of pentagastrin on respiration and the
impact of CI (designed to reduce novelty and increase
control and coping) on respiratory responses. We
hypothesized that pentagastrin would stimulate respira-
tion, evidenced by reduced PETCO2, and that CI would
attenuate this hyperventilation. Given the limitations of
an add-on study, these data must be considered
preliminary, but are informative for future studies.
METHODS
DESIGN
Respiratory data using a hand-held capnograph were obtained on
24 of 40 subjects studied in a pentagastrin challenge paradigm,[17]
using a single-blind, placebo-controlled design. The study was
reviewed and approved by the University of Michigan Institutional
Review Board. Subjects, who were blinded to the condition, always
received placebo on the first day and then returned 1–7 days later for
the pentagastrin injection. Subjects were randomly assigned to
receive either standard instructions or a CI (see below).
SUBJECTS
Subjects were recruited through advertisement and paid $200.
Informed consent was obtained after the nature of the procedures was
explained. Subjects were 18–44 years old and medically healthy,
without history of alcohol or drug dependence, recent drug or
alcohol abuse (6 months), or past or present psychiatric disorder (by
SCID). They were of normal weight, with low levels of tobacco (one
subject 10 cigarettes per day and two subjects 1 cigarette every 1–2
days) and alcohol use (o5 drinks per week), and had normal
screening labs. Female subjects were pre-menopausal, not on birth
control pills, and were studied in the first 10 days after menstruation
onset.
PROCEDURES
Subjects reported at 1 pm for experimental sessions. Use of food and
tobacco was prohibited subsequent to their arrival. The investigator
administered instructions identically on each visit via a 5 min audio
tape for standard instructions or a 9 min tape and a 5 min discussion for
the cognitive intervention. An intravenous catheter (saline drip) was
inserted into an antecubital vein at approximately 1:30 pm. Subjects
rested in bed for 1.5 hr (reading, studying, listening to music) to
accommodate to the setting. At 3 pm, a capnograph that samples
PETCO2 and RR via a nasal canula, and HR through pulse oximetry,
was attached for continuous monitoring until 5.00 pm. Baseline blood
samples were obtained at 3 pm and 3:28 pm. The investigator returned
at 3:30 pm (behind a curtain, out of subject’s awareness) to inject (over
15 sec) the placebo or pentagastrin (0.06mg/kg; Wyeth-Ayerst,
Philadelphia, PA, or Calbiochem-Novabiochem, Laufelfingen,
Switzerland). Blood samples were obtained 3, 5, 10, 20, 30, 45, and
60 min after injection.
INSTRUCTIONS
The Standard Instruction (SI) group received basic instructions
describing procedures, apparatus, and common side effects of
pentagastrin. The CI group received two additional techniques,
labeled ‘‘coping’’ and ‘‘control.’’ The coping component included a
more detailed description of expectable responses (to reduce novelty)
and coaching to attribute these responses to normal reactions to
pentagastrin rather than anything dangerous (to facilitate ‘‘cognitive
coping’’). The control component gave subjects permission to use
infusion pump controls to stop the drug infusion, if they wished to do
so. For the larger neuroendocrine study, the CI group was divided
into subgroups (full intervention, coping alone, control alone groups)
to dismantle which intervention factor modulates neuroendocrine
responses. Details are available elsewhere.[16] Respiratory monitoring
was added later in the study only for the last 24 subjects, and for these
analyses the CI subgroups were combined.
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MEASURES, INSTRUMENTS, ANALYSES
The Beck Depression Inventory (BDI), Spielberger State-Trait
Anxiety Index (STAI), and Anxiety Sensitivity Index (ASI) were
administered at screening. Visual analog scales (100 mm lines
anchored from ‘‘not at all’’ to ‘‘most ever’’) for anxiety, fear,
nervousness, and calm were combined to quantify subjective anxious
distress during the experiment. Panic symptoms and pentagastrin side
effects were rated on a 4-point scale (none, mild, moderate, severe)
using a modified acute panic inventory,[3] and summed to quantify
total symptom intensity. PETCO2, HR, and RR were recorded using a
TIDAL WAVE Sp Handheld Mainstream Capnograph with Pulse
Oximetry and Sidestream Sampling (Model 715/B) (Respironics
Novametrix, CT). Cortisol was assayed using the Coat-Account assay
from Diagnostic Products Corporation (Los Angeles, CA) with a
sensitivity of 0.2mg/dl.
Respiratory data were collected for 6 min before and 3 min
following pentagastrin infusion. The 3 min cutoff was necessary
because subjects verbally described symptoms between 3–5 min after
infusion, and speaking disrupts capnograph accuracy. Respiratory
and cardiac data were averaged at 64 sec intervals, as the device
recorded values every 8 sec. Outliers were excluded as follows:
PETCO2 o10 and 450, RR o3 or 430, HR o30 or 4160.
Repeated measures analyses of variance (RM-ANOVAs) were used
to evaluate treatment (placebo versus pentagastrin), time (pre- to
post-injection), and interaction effects for heart rate, PETCO2, and
cortisol. Between subjects RM-ANOVA was used to evaluate group
(SI versus CI), time, and interaction effects for PETCO2. Response
measures (post-pentagastrin peak minus baseline) were used in
regression analyses.
RESULTS
Subjects were 25.177.6 (SD) years old, with equal
percentages of males and females (50%) in the SI
(n 5 6) and CI (n 5 18) groups. CI subgroups did not
differ from each other on baseline measures or cortisol,
PETCO2, HR, RR, anxious distress, or panic symptom
responses to pentagastrin (P4.3). There were no
differences between SI and CI groups in age, weight,
pentagastrin dose, stress rating, ASI (6.1677.78 versus
11.2274.67) or BDI (1.1672.04 versus 0.9471.35).
The two groups did differ in STAI-trait anxiety
(34713.49 versus 25.7273.38; t22 5 2.44, Po.03).
RESPONSE TO DRUG
Subjects responded differently to pentagastrin than
placebo in heart rate (drug-by-time interaction,
F3,69 5 35.55, P 5.0001), cortisol (F6,132 5 23.91,
P 5.0001), and PETCO2 (F3,69 5 8.28, P 5.0001),
owing to pentagastrin-induced elevations in HR and
cortisol and a fall in PETCO2 (Fig. 1), with no placebo
day changes. Mean baseline PETCO2 was 41.6 mmHg,
which dropped to a mean trough of 38.4 within 3 min
post-pentagastrin. The average PETCO2 drop was
3.2 mmHg with a range of 0.1–13.9. Despite evidence
of respiratory stimulation (fall in PETCO2), RR did not
change with pentagastrin, but rose slightly with
placebo (Fig. 1; drug-by-time interaction effect
marginally significant, F3,69 5 2.54, P 5.06). Subjects
reported greater panic symptom intensity 3 min after
pentagastrin (M 5 10.67 SD 5 7.0) compared to place-
bo (M 5 0.83 SD 5 1.71) (t23 5 7.35, P 5.0001). Three
out of 24 subjects had a panic attack (at least 4
symptoms rated mild or higher on the acute panic
inventory and 2-point or greater increase in anxiety/
fear).
The CI significantly reduced the PETCO2 response
to pentagastrin (Fig. 2; group-by-time interaction
F3,66 5 3.30, P 5.03), but not HR (F 5 0.208, P 5.89)
nor RR (F 5 0.89, P 5.45). STAI-trait anxiety was
elevated in the SI group (see above) and controlling for
this variable in a repeated measures ANCOVA under-
mined the significance of the PETCO2 group-by-time
interaction (F3,63 5 1.26, P 5.30). The direct relation-
ship between STAI-trait and PETCO2 was relatively
weak (r 5 .384, P 5.07, n 5 24), especially within the
CI group (r 5 .064, P 5.8, n 5 18).
CORRELATIONS
The PETCO2 response to pentagastrin correlated with
panic symptom intensity (r 5 .709, P 5.0001, n 5 24),
but not with anxious distress (r 5 .329, P 5.117, n 5 24).
The RR response did not correlate with panic symptom
intensity (P4.59) or with anxious distress (P4.37). The
cortisol response was significantly correlated with the
Figure 1. Left panel: Respiratory rate for 24 subjects before and after drug injection on pentagastrin and placebo days (means7SE).
Right panel: PETCO2 levels before and after injection for 24 subjects on pentagastrin and placebo days (means7SE).
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PETCO2 response (r 5 .417, P 5.048, n 5 23), but not
with the RR response (P 5.48).
To insure that significant correlations were not
secondary to SI/CI group differences, they were repeated
in the CI group alone (n 5 18). PETCO2 remained
correlated with panic symptom intensity response
(r 5 .64, P 5.015) and cortisol (r 5 .564, P 5.015).
DISCUSSION
These data indicate that pentagastrin is a respiratory
stimulant that can produce transiently increased
ventilation in healthy subjects and suggest that it does
so by increasing tidal volume. Unfortunately, we did
not have the instrumentation to record Vt, so direct
evidence for its increase is still needed. Nonetheless,
the fall in PETCO2 without change in RR strongly
suggests that Vt increased. The only study to our
knowledge that looked at the impact of a related
CCK-B agonist (CCK4) on PETCO2 found no effect.
[8]
An earlier study that did not measure PETCO2 did
directly demonstrate hyperventilation in response to
CCK4, driven by Vt and not RR.[7] However, another
study using pentagastrin showed changes in both Vt
and RR in healthy subjects.[18] These discrepancies may
reflect differences in drug doses or subject character-
istics. The Schruers et al. study purposely used a low
drug dose to examine effects of arousal and showed no
effect on respiratory parameters despite small but
statistically significant effects on heart rate, panic, and
anxiety symptoms. The Lara et al. study used a higher
dose and examined only those subjects who responded
to pentagastrin with panic, and was the only one to
show an effect on RR. The CCK4 study and our study
included many subjects who did not panic. Increased
RR may be a function of panic and not a direct drug
effect, whereas reduction in PETCO2, likely owing to
Vt increase, may be a direct drug effect that is dose
dependent. A recent study of blood phobia suggests
that Vt increase may be more strongly linked to
physical symptoms (e.g., dizziness and feeling faint)
than RR, and may play a more prominent role in
anxiety.[19] If pentagastrin directly stimulates increases
in tidal volume, this may well contribute to its
panicogenic potency in vulnerable subjects, with
additional respiratory drive that leads to increased RR
appearing secondarily when panic in fact occurs.
If respiratory stimulation does contribute to penta-
gastrin-induced panicogenesis, the precise pathway
remains unclear, and this study of healthy subjects
can provide only limited information. However, the
correlation between PETCO2 and panic symptom
intensity was driven in our subjects entirely by physical
symptom ratings, in the absence of any link to anxious
distress. Though the total amount of hyperventilation
produced was relatively mild (mean drop of
3.17 mmHg in PETCO2), those subjects with the
greatest falls were the ones who reported developing
physical symptoms. This suggests that if respiratory
stimulation plays a role in pentagastrin’s panic symp-
tom generation it might do so indirectly through
hyperventilation-related physical sensations, rather
than via a direct link between respiratory control
centers and anxiogenesis. Such physical sensations may
have particular salience to panic-prone people, either
because they are reminiscent of previously experienced
panic attacks or because they may have particular
salience to processors in the brain that attach affective
tone to bodily sensations (see below). Such indirect
pathways are consistent with growing evidence that
respiratory abnormalities are not a fundamental feature
of patients with panic disorder,[20,21] so respiratory
centers may not play as central a role in panic as once
thought.[9]
Other pathways are clearly possible and further
research is needed. The link between hyperventilation
and physical symptoms in this study was correlational
and the overall group reductions in PETCO2 were not
large, so it is possible that the physical sensations
reminiscent of panic reported by our subjects were not
a consequence of hyperventilation itself. Pentagastrin
could produce panic through other pathways, such as
hypersensitive CCK-B receptors in the amygdala,[22]
which could cause both increased respiratory drive and
physical sensations, even without a direct link between
the two.
As with doxapram, a CI designed to reduce novelty
and increase coping and sense of control significantly
attenuated the hyperventilation produced by pentagas-
trin. This suggests that whatever the mechanism of
CCK-B-mediated respiratory stimulation, top–down
modulation through higher-level processing of the
sensory experiences can attenuate it. The strength of
this conclusion is weakened by the fact that some of the
variance in respiratory response was captured by a
group difference in trait anxiety. Further work with
larger and better matched groups is needed to clarify
whether CI reduced hyperventilation in the CI group
Figure 2. PETCO2 levels (means7SE) on pentagastrin day for
the Standard Instruction group (n 5 6) and the Cognitive
Intervention group (n 5 18). The cognitive intervention was
designed to enhance coping and sense of control.
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or trait anxiety increased hyperventilation in the SI
group. Interestingly, neither state nor trait anxiety
directly predicted respiratory response. We hypothe-
size that both the CI and trait anxiety contributed to
the group difference detected but, with a small sample,
we did not have sufficient power to see the independent
effects of both. Though there are a variety of
mechanisms through which trait anxiety could impact
respiration, a trait anxiety effect, like the CI effect, is
compatible with the hypothesis that higher order,
cortical, and/or limbic inputs can modulate outputs
of physiological control centers and may be relevant to
psychophysiological abnormalities detected in patients
with anxiety disorders.
Growing evidence supports the hypothesis of
bi-directional interaction between cortical–limbic/
cognitive–emotional control circuits in the brain and
respiratory phenomena. Shortness of breath or air
hunger is a highly distressing experience that activates
limbic and paralimbic brain regions, including anterior
insula and cingulate, amygdala, thalamus, and basal
ganglia.[23,24] As with pain, the affective dimension of
this experience is processed separately from the sensory
intensity dimension,[25] with affective evaluation pro-
cessed through limbic pathways (involving insular
cortex, amygdala, cingulate cortex, and medial thala-
mus).[26] These limbic regions are in turn linked to
respiratory control centers, providing a loop through
which affective experience can be generated by
respiratory-related sensations and can in turn shape
autonomic and respiratory responses.[27,28] Intrigu-
ingly, limbic regions involved in emotional processing,
such as insula, amygdala, and hippocampus, may be
particularly involved in modulating the phasic aspects
of breathing that produce sighs,[29–32] which may
have particular relevance to anxiety disorders.[33,34]
There is evidence that these same regions provide
cognitive–emotional modulation of HPA axis activity,[35]
and shared links to the same cognitive–emotional control
regions may create the link between HPA axis reactivity
and PETCO2 seen in this study. An even stronger link
between the HPA axis and respiration was seen in our
doxapram study, where the respiratory-dependent
variable was rhythm irregularity created by sighs.[16]
A similar link may well have been seen here, but the
capnograph unfortunately did not provide us with the
Vt date needed to track sighs. Deeper understanding of
potential linkages between anxiety, sighs, and HPA axis
activity that may be created by shared modulation
through top–down cognitive control regions of the
brain could be extremely helpful in efforts to dissect the
central pathophysiology of a number of psychiatric
disorders.[36]
These data have significant limitations, including a
small sample size, an unexpected group difference in
trait anxiety despite random assignment, and an
absence of Vt measures. However, they have implica-
tions for future studies. Potential links between HPA
axis reactivity and respiratory abnormalities in anxious
patients may be particularly useful clues to pursue,
because shared input from cortical–limbic processors
may provide the common thread that helps locate the
real source of the dysregulation that creates abnorm-
alities in both systems. Further study of the interactions
between HPA axis and respiratory dysregulation in
psychiatric disorders may be quite fruitful. It will be
important in future work to utilize technology that
allows simultaneous measurement of tidal volume,
PETCO2, RR, and HPA axis hormones.
CONCLUSION
We found that in a healthy population, pentagastrin
stimulates respiration, likely via increases in tidal
volume, and that respiratory stimulation could play a
role in its panicogenic potency through hyperventila-
tion-related physical sensations. Additionally, penta-
gastrin-induced hyperventilation can perhaps be
modulated by a CI, which also attenuates both panic
and HPA responses. Although the strength of this
conclusion is weakened by a trait anxiety confound
between groups, the trait anxiety effect, like the CI
effect, is compatible with the hypothesis that higher
order, cortical, and/or limbic inputs can modulate
outputs of physiological control centers and may be
relevant to psychophysiological abnormalities detected
in patients with anxiety disorders.
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